![]() Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on Canada.ca. As of November 4, 2023, 3 TTS, 36 myocarditis/pericarditis, 4 GBS and 0 CLS cases have been reported in Saskatchewan. There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. Not inclusive of all AEFIs that can be reported (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline. CAMBRIDGE, MA / ACCESSWIRE / Ap/ Moderna, Inc. Table 2: Cumulative Frequency of AEFIs Reported Adverse event type Company establishes 2027 financial framework for the Respiratory Franchise. Serious AEFI reporting rate per 1,000 doses administeredġSerious criteria includes an adverse event that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation. ![]() Total AEFI reporting rate per 1,000 doses administered Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of November 4, 2023 Refer to Tables 1 and 2 for more details.ĪEFI Reports are updated every 4 weeks. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.Īs of November 4, 2023, a cumulative total of 1,390 reportable AEFI reports have been received, following 3,006,115 doses of COVID-19 vaccines administered in Saskatchewan with a reporting rate of 0.46 per 1,000 doses administered (0.046% of all doses administered). Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).Īny person or entities that rely on information obtained from the system does so at his or her own risk. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. The translation should not be considered exact, and may include incorrect or offensive language. Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Where an official translation is not available, Google™ Translate can be used. The home page for French-language content on this site can be found at: Then call your local VA health facility to verify. These translations are identified by a yellow box in the right or left rail that resembles the link below. If someone calls you from VA and you don’t recognize the phone number, ask for a number to call them back. Anonymised data from individual adverse reaction reports submitted to the EMA are publically accessible for review at number of pages on the Government of Saskatchewan's website have been professionally translated in French. These reports (with personal details excluded) are subsequently sent to EudraVigilance, the European Medicines Agency’s (EMA’s) database of suspected adverse reactions, where the data are analysed to detect new safety signals. side effect) reportsĪdverse reaction reports received by the HPRA are processed and entered into the national database. Healthcare Professionals and Pharmacovigilance Access to information from adverse reaction (i.e. ![]() This page provides more information about side effects and why it is important that they are reported to the HPRA. We have published a medicines and side effects consumer information page. You can e-mail completed forms to By printing our adverse reaction report form ( Word version) and posting a completed copy to the HPRA by freepost. By downloading a copy of our adverse reaction report form ( Word version).To your doctor, pharmacist or nurse who can then notify the HPRA.You can report a suspected side effect in a number of ways: For more information, please visit COVID-19 vaccines and treatments: Reporting a side effect. To report a suspected adverse reaction (side effect) to a COVID-19 vaccine, please visit our Report an Issuewebpage. COVID-19 vaccines: Reporting suspected side effects
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |